Strongly


An expression of the live unlimited spirit, stories and voices of the MDA community

Some some said she’d never have a family, a career or a full life. Lorraine Woodward said “Watch me!”

At the age of 2, Lorraine Woodward was diagnosed with limb-girdle muscular dystrophy (LGMD), and doctors told her parents that she would not live past 16 years old. Now, at age 54, she has more than outlived those early predictions and made a successful life as a wife, mother, volunteer and entrepreneur. From an early age Lorraine . . .

Read More

Building Stronger Futures Together to Help Families Live Unlimited

As MDA’s top Shamrocks retailer and a huge supporter of MDA Summer Camp, Lowe’s has helped families live unlimited. Since 2001, they have raised more than $57 million through MDA’s Shamrocks program to help improve lives in hometowns across America and build stronger futures for kids and adults with muscular dystrophy, ALS and related life-threatening . . .

Read More

Epic Costumes for Extraordinary Kids: Non-Profit Helps Kids in Wheelchairs Live Unlimited

Halloween is a night when kids can be whatever they want to be. They can dress as ghosts, cowboys, astronauts, monsters — the sky’s the limit. That’s exactly what Ryan Wiemer tells the kids he works with. The sky’s the limit. His non-profit, called Magic Wheelchair, helps kids live unlimited by designing and building special costumes. But . . .

Read More

Experimental Mitochondrial Myopathy Treatment Shows Encouraging Results in Phase 2 Trial

Stealth Bio Therapeutics has reported encouraging results from a phase 2 clinical trial to evaluate elamipretide for the treatment of muscle weakness caused by mitochondrial disease. Elamipretide is an experimental drug designed to modify disease by helping to restore normal energy production in mitochondria and decrease oxidative stress. In the completed MMPOWER trial, investigators treated . . .

Read More

BioMarin Discontinues Development of Pompe Drug  

  BioMarin Pharmaceutical has announced that it is discontinuing development of BMN 701, an enzyme replacement therapy (ERT) for the treatment of Pompe disease (acid maltase deficiency, or AMD). In Pompe, a deficiency of an enzyme called acid alpha-glucosidase helps break down sugar stored in cells (glycogen). Without this enzyme, glycogen accumulates in cells and . . .

Read More